ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 937,90
-0,75%
Dow Jones
38 711,29
0,36%
DAX
18 405,64
-1,10%
Brent Oil
77,11
-1,32%
Bitcoin
70 693,82
2,75%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Brooklyn ImmunoTherapeutics Inc (BTX)

  7. Brooklyn ImmunoTherapeutics Inc (BTX) Actualités

BTX

Brooklyn ImmunoTherapeut... (BTX)

Brooklyn ImmunoTherapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:BTX
DateHeureSourceTitreSymboleSociété
11/05/202322h35Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
10/05/202312h02Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
05/05/202313h02Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
05/05/202313h01Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
05/05/202312h31Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
25/04/202315h02Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
20/04/202322h31Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
04/04/202323h15Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
04/04/202323h05Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
20/12/202222h31Edgar (US Regulatory)Statement of Beneficial Ownership (sc 13d)NASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
16/12/202223h01Edgar (US Regulatory)Small Company Offering and Sale of Securities Without Registration (d)NASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
14/12/202222h31Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
07/12/202200h52Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
02/12/202223h01Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
11/10/202214h30GlobeNewswire Inc.Brooklyn ImmunoTherapeutics Announces Name Change to Eterna Therapeutics and Provides Corporate UpdatesNASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
26/07/202213h30GlobeNewswire Inc.Brooklyn ImmunoTherapeutics Announces Results of Phase 2 Study of IRX-2 in Head and Neck CancerNASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
17/06/202223h00GlobeNewswire Inc.Brooklyn ImmunoTherapeutics Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price DeficiencyNASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
07/06/202213h30GlobeNewswire Inc.Brooklyn ImmunoTherapeutics Announces Board ChangesNASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
31/05/202213h30GlobeNewswire Inc.Brooklyn ImmunoTherapeutics Announces Changes to Executive Management: Matt Angel, Ph.D. Appointed Interim Chief Executive Officer and President, Andrew Jackson Appointed Chief Financial Officer Postpones 2022 Annual MeetingNASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
27/05/202222h30GlobeNewswire Inc.Brooklyn ImmunoTherapeutics Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Quarterly Report on Form 10-QNASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
19/05/202214h23GlobeNewswire Inc.Amarin Announces Appointment of New Directors and Board Leadership ChangesNASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
29/04/202222h35Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)NASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
21/04/202213h30GlobeNewswire Inc.Brooklyn ImmunoTherapeutics Announces Establishment of New Research and Development Facility for Advancement of Engineered Cellular MedicinesNASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
15/04/202223h10Edgar (US Regulatory)Annual Report (10-k)NASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
15/04/202222h15GlobeNewswire Inc.Brooklyn ImmunoTherapeutics Announces Fourth Quarter and Full Year 2021 Financial ResultsNASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
01/04/202212h31Edgar (US Regulatory)Notification That Annual Report Will Be Submitted Late (nt 10-k)NASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
09/03/202222h15GlobeNewswire Inc.Brooklyn ImmunoTherapeutics Announces Closing of $12 Million Private PlacementNASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
07/03/202214h00GlobeNewswire Inc.Brooklyn ImmunoTherapeutics Announces $12 Million Private PlacementNASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
20/01/202213h30GlobeNewswire Inc.Brooklyn ImmunoTherapeutics Welcomes Erin S. Enright and Heather B. Redman to Its Board of DirectorsNASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
13/01/202214h30GlobeNewswire Inc.Brooklyn ImmunoTherapeutics Provides Update on Regenerative Medicine Intellectual Property PortfolioNASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:BTX

Dernières Valeurs Consultées

USI
USTECH100
US Tech 100
NASDAQ
AMZN
Amazon.com
FTSE
UKX
FTSE 100
SPI
SP500
S&P 500
EU
EN
Bouygues
EU
DG
Vinci
EU
AF
Air FranceKLM
EU
PX1
CAC 40
NYSE
DIS
Walt Disney
COIN
BTCUSD
Bitcoin
EU
LR
Legrand
EU
BNP
BNP Paribas
EU
ML
Michelin
EU
BN
Danone
EU
RI
Pernod Ricard
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés